Market Overview

UPDATE: Jefferies Raises PT on Eli Lilly & Co. as Least-Preferred Name

Related LLY
The Market In 5 Minutes: UA, GM, P&G Earnings On The Street's Mind
A Peek Into The Markets: U.S. Stock Futures Rise; GM, Apple Earnings In Focus
Eli Lilly Q3 top line up 5%; net income down 3%; shares off 1% premarket (Seeking Alpha)

In a report published Wednesday, Jefferies analyst Jeffrey Holford reiterated an Underperform rating on Eli Lilly & Co. (NYSE: LLY), and slightly raised the price target from $43.00 to $44.00.

In the report, Holford noted, “We remain positive on Pharmaceuticals and see valuation as attractive for most stocks. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche and Pfizer remain high conviction Buy ratings. We point to Eli Lilly and GlaxoSmithKline as least preferred names.”

Eli Lilly & Co. closed on Tuesday at $56.74.

Latest Ratings for LLY

Sep 2016Goldman SachsUpgradesNeutralBuy
Sep 2016JP MorganMaintainsOverweight
Sep 2016JP MorganUpgradesNeutralOverweight

View More Analyst Ratings for LLY
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings


Related Articles (LLY)

View Comments and Join the Discussion!